Landscapes / Companies

Incyte Corporation not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
6 approved
4 in Phase 3
Next date
Povorcitinib, Phase 2 trial completes
Drugs
19
in active trials · 45 in all
Trials
53 active
215 since 2021

Drugs19

DrugHow it worksPartnerStageNext dateDetails
Janus kinase inhibitor
Approved in the EU 20 Nov 2026soonPhase 2 trial completes
Programmed death receptor-1 blocking antibody
Approved 1 Jan 2027Phase 1 trial completes
Monoclonal antibody
Incyte · Syndax Pharmaceuticals
Approved 6 Jan 2027Phase 1/2 trial completes
Ruxolitinibnot checked
Kinase Inhibitor; janus kinase inhibitor
Incyte · Novartis Pharmaceuticals
Approved 30 Apr 2027Phase 3 trial completes
Monoclonal antibody
MorphoSys
Approved 29 Aug 2027Phase 2 trial completes
Kinase inhibitor
Approved 25 Feb 2031Phase 2 trial completes
—
Phase 3 27 Apr 2027Phase 2 trial completes
—
Phase 3 15 Sep 2028Phase 3 trial completes
—
Phase 3 29 Dec 2028Phase 3 trial completes
—
Phase 3 15 Jun 2029Phase 3 trial completes
—
Phase 2 30 Jul 2027Phase 2 trial completes
—
Phase 2 23 Sep 2027Phase 2 trial completes
—
Phase 1 27 Mar 2027Phase 1 trial completes
—
Phase 1 30 Apr 2027Phase 1 trial completes
—
Phase 1 27 Jul 2027Phase 1 trial completes
—
Phase 1 14 Mar 2028Phase 1 trial completes
—
Phase 1 18 Aug 2028Phase 1 trial completes
—
Phase 1 9 Oct 2028Phase 1 trial completes
—
Phase 1 24 May 2030Phase 1 trial completes

About

No active trial
26 other drugs
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Incyte Corporation

Following is part of Solo: you see every change to Incyte Corporation the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in